[What is really an optimal treatment in type 2 diabetes? New studies call for reflection].
Nilsson
Peter M
PM
Institutionen för kliniska vetenskaper, Universitetssjukhuset MAS, Malmö. peter.nilsson@med.lu.se
Eliasson
Björn
B
D002318:Cardiovascular Diseases / Q000209:etiology; D048909:Diabetes Complications / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D012307:Risk Factors
D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; C517652:hemoglobin A1c protein, human